Half-year report · Q2
9265.TEDINET S100V29Y
Period2024-06-01 → 2024-11-30
Filed2025-01-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥31.4bn | 2024-06-01 → 2024-11-30 | Cons. | Net sales |
| Revenue | ¥61.6bn | 2023-06-01 → 2024-05-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥28.9bn | 2023-06-01 → 2023-11-30 | Cons. | Net sales |
| Operating income | ¥522m | 2024-06-01 → 2024-11-30 | Cons. | Operating income |
| Operating income | ¥618m | 2023-06-01 → 2023-11-30 | Cons. | Operating income |
| Ordinary income | ¥552m | 2024-06-01 → 2024-11-30 | Cons. | Ordinary income |
| Ordinary income | ¥1.0bn | 2023-06-01 → 2024-05-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥645m | 2023-06-01 → 2023-11-30 | Cons. | Ordinary income |
| Profit before tax | ¥586m | 2024-06-01 → 2024-11-30 | Cons. | Income before income taxes |
| Profit before tax | ¥700m | 2023-06-01 → 2023-11-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥338m | 2024-06-01 → 2024-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥580m | 2023-06-01 → 2024-05-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥480m | 2023-06-01 → 2023-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥337m | 2024-06-01 → 2024-11-30 | Cons. | Profit loss |
| Net income | ¥477m | 2023-06-01 → 2023-11-30 | Cons. | Profit loss |
| Total assets | ¥26.4bn | at 2024-11-30 | Cons. | Assets |
| Total assets | ¥26.6bn | at 2024-05-31 | Cons. | Assets |
| Total assets | ¥24.8bn | at 2023-11-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥17.7bn | at 2024-11-30 | Cons. | Liabilities |
| Total liabilities | ¥18.0bn | at 2024-05-31 | Cons. | Liabilities |
| Net assets / equity | ¥8.7bn | at 2024-11-30 | Cons. | Net assets |
| Net assets / equity | ¥8.6bn | at 2024-05-31 | Cons. | Net assets |
| Net assets / equity | ¥8.3bn | at 2023-11-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥4.4bn | at 2024-11-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥5.3bn | at 2024-05-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥4.4bn | at 2024-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.3bn | at 2024-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.0bn | at 2023-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.8bn | at 2023-05-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥633m | 2024-06-01 → 2024-11-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥878m | 2023-06-01 → 2024-05-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥544m | 2023-06-01 → 2023-11-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | ¥19m | 2024-06-01 → 2024-11-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.1bn | 2023-06-01 → 2024-05-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥154m | 2023-06-01 → 2023-11-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥239m | 2024-06-01 → 2024-11-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥335m | 2023-06-01 → 2024-05-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥123m | 2023-06-01 → 2023-11-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥136.8 | 2024-06-01 → 2024-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥227.96 | 2023-06-01 → 2024-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥188.05 | 2023-06-01 → 2023-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 32.9% | at 2024-11-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.2% | at 2024-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.5% | at 2023-11-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 36
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2024-06-01 → 2024-11-30 | ¥0 |
| Reconciling Itemsreconciling | revenue intersegment | 2024-06-01 → 2024-11-30 | ¥0 |
| Reconciling Itemsreconciling | segment profit | 2024-06-01 → 2024-11-30 | −¥519m |
| jpcrp040300-q2r_E33393-000Medical Equipment Manufacturing And Salesreportable segment | revenue | 2024-06-01 → 2024-11-30 | ¥113m |
| jpcrp040300-q2r_E33393-000Medical Equipment Manufacturing And Salesreportable segment | revenue external | 2024-06-01 → 2024-11-30 | ¥112m |
| jpcrp040300-q2r_E33393-000Medical Equipment Manufacturing And Salesreportable segment | revenue intersegment | 2024-06-01 → 2024-11-30 | ¥0 |
| jpcrp040300-q2r_E33393-000Medical Equipment Manufacturing And Salesreportable segment | segment profit | 2024-06-01 → 2024-11-30 | −¥82m |
| jpcrp040300-q2r_E33393-000Medical Equipment Salesreportable segment | revenue | 2024-06-01 → 2024-11-30 | ¥31.2bn |
| jpcrp040300-q2r_E33393-000Medical Equipment Salesreportable segment | revenue external | 2024-06-01 → 2024-11-30 | ¥31.2bn |
| jpcrp040300-q2r_E33393-000Medical Equipment Salesreportable segment | revenue intersegment | 2024-06-01 → 2024-11-30 | ¥0 |
| jpcrp040300-q2r_E33393-000Medical Equipment Salesreportable segment | segment profit | 2024-06-01 → 2024-11-30 | ¥1.1bn |
| jpcrp040300-q2r_E33393-000Medical Mallreportable segment | revenue | 2024-06-01 → 2024-11-30 | ¥35m |
| jpcrp040300-q2r_E33393-000Medical Mallreportable segment | revenue external | 2024-06-01 → 2024-11-30 | ¥35m |
| jpcrp040300-q2r_E33393-000Medical Mallreportable segment | segment profit | 2024-06-01 → 2024-11-30 | ¥0 |
| —segment total | revenue | 2024-06-01 → 2024-11-30 | ¥31.4bn |
| —segment total | revenue external | 2024-06-01 → 2024-11-30 | ¥31.4bn |
| —segment total | revenue intersegment | 2024-06-01 → 2024-11-30 | ¥0 |
| —segment total | segment profit | 2024-06-01 → 2024-11-30 | ¥1.0bn |
| Reconciling Itemsreconciling | revenue | 2023-06-01 → 2023-11-30 | ¥0 |
| Reconciling Itemsreconciling | revenue intersegment | 2023-06-01 → 2023-11-30 | ¥0 |
| Reconciling Itemsreconciling | segment profit | 2023-06-01 → 2023-11-30 | −¥494m |
| jpcrp040300-q2r_E33393-000Medical Equipment Manufacturing And Salesreportable segment | revenue | 2023-06-01 → 2023-11-30 | ¥146m |
| jpcrp040300-q2r_E33393-000Medical Equipment Manufacturing And Salesreportable segment | revenue external | 2023-06-01 → 2023-11-30 | ¥146m |
| jpcrp040300-q2r_E33393-000Medical Equipment Manufacturing And Salesreportable segment | revenue intersegment | 2023-06-01 → 2023-11-30 | ¥0 |
| jpcrp040300-q2r_E33393-000Medical Equipment Manufacturing And Salesreportable segment | segment profit | 2023-06-01 → 2023-11-30 | ¥6m |
| jpcrp040300-q2r_E33393-000Medical Equipment Salesreportable segment | revenue | 2023-06-01 → 2023-11-30 | ¥28.7bn |
| jpcrp040300-q2r_E33393-000Medical Equipment Salesreportable segment | revenue external | 2023-06-01 → 2023-11-30 | ¥28.7bn |
| jpcrp040300-q2r_E33393-000Medical Equipment Salesreportable segment | revenue intersegment | 2023-06-01 → 2023-11-30 | ¥0 |
| jpcrp040300-q2r_E33393-000Medical Equipment Salesreportable segment | segment profit | 2023-06-01 → 2023-11-30 | ¥1.1bn |
| jpcrp040300-q2r_E33393-000Medical Mallreportable segment | revenue | 2023-06-01 → 2023-11-30 | ¥36m |
| jpcrp040300-q2r_E33393-000Medical Mallreportable segment | revenue external | 2023-06-01 → 2023-11-30 | ¥36m |
| jpcrp040300-q2r_E33393-000Medical Mallreportable segment | segment profit | 2023-06-01 → 2023-11-30 | ¥2m |
| —segment total | revenue | 2023-06-01 → 2023-11-30 | ¥28.9bn |
| —segment total | revenue external | 2023-06-01 → 2023-11-30 | ¥28.9bn |
| —segment total | revenue intersegment | 2023-06-01 → 2023-11-30 | ¥0 |
| —segment total | segment profit | 2023-06-01 → 2023-11-30 | ¥1.1bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 485
| Item | Context | Value | Unit |
|---|---|---|---|
| Payments for lease and guarantee deposits inv cf | Prior1YTDDuration | -53000000 | JPY |
| Payments for lease and guarantee deposits inv cf | CurrentYTDDuration | － | JPY |
| Purchase of investments in subsidiaries resulting in change in scope of consolidation inv cf | Prior1YTDDuration | -21000000 | JPY |
| Purchase of investments in subsidiaries resulting in change in scope of consolidation inv cf | CurrentYTDDuration | － | JPY |
| Proceeds from purchase of investments in subsidiaries resulting in change in scope of consolidation inv cf | Prior1YTDDuration | － | JPY |
| Proceeds from purchase of investments in subsidiaries resulting in change in scope of consolidation inv cf | CurrentYTDDuration | 339000000 | JPY |
| Other net inv cf | Prior1YTDDuration | 0 | JPY |
| Other net inv cf | CurrentYTDDuration | 0 | JPY |
| Net cash provided by used in investment activities | Prior1YTDDuration | -154000000 | JPY |
| Net cash provided by used in investment activities | CurrentYTDDuration | 19000000 | JPY |
| Purchase of treasury stock fin cf | Prior1YTDDuration | － | JPY |
| Purchase of treasury stock fin cf | CurrentYTDDuration | -65000000 | JPY |
| Cash dividends paid fin cf | Prior1YTDDuration | -122000000 | JPY |
| Cash dividends paid fin cf | CurrentYTDDuration | -173000000 | JPY |
| Other net fin cf | Prior1YTDDuration | -1000000 | JPY |
| Other net fin cf | CurrentYTDDuration | － | JPY |
| Net cash provided by used in financing activities | Prior1YTDDuration | -123000000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration | -239000000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | -823000000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | -853000000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 5825000000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 5300000000 | JPY |
| Cash and cash equivalents | Prior1QuarterInstant | 5002000000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 4447000000 | JPY |
| Salaries and allowances sga | Prior1YTDDuration | 1656000000 | JPY |
| Salaries and allowances sga | CurrentYTDDuration | 1826000000 | JPY |
| Provision for bonuses sga | Prior1YTDDuration | 184000000 | JPY |
| Provision for bonuses sga | CurrentYTDDuration | 188000000 | JPY |
| Retirement benefit expenses sga | Prior1YTDDuration | 78000000 | JPY |
| Retirement benefit expenses sga | CurrentYTDDuration | 55000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E33393-000MedicalEquipmentSalesReportableSegmentsMember | 28716000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E33393-000MedicalEquipmentManufacturingAndSalesReportableSegmentMember | 146000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E33393-000MedicalMallReportableSegmentsMember | 36000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReportableSegmentsMember | 28899000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 28899000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E33393-000MedicalEquipmentSalesReportableSegmentsMember | 0 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E33393-000MedicalEquipmentManufacturingAndSalesReportableSegmentMember | 0 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E33393-000MedicalMallReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_ReportableSegmentsMember | 0 | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | -0 | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E33393-000MedicalEquipmentSalesReportableSegmentsMember | 28717000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E33393-000MedicalEquipmentManufacturingAndSalesReportableSegmentMember | 146000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E33393-000MedicalMallReportableSegmentsMember | 36000000 | JPY |
| Net sales | Prior1YTDDuration_ReportableSegmentsMember | 28900000000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | -0 | JPY |
| Net sales | Prior1YTDDuration | 28899000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E33393-000MedicalEquipmentSalesReportableSegmentsMember | 1104000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E33393-000MedicalEquipmentManufacturingAndSalesReportableSegmentMember | 6000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |